|
|
Written by RESprotect GmbH
|
|
Tuesday, 31 March 2009 |
RESprotect Elucidates The Mode Of Action Of Its Anti-Cancer Drug RP101: Binding To Heat Shock Protein Hsp27
Dresden, Germany – March 31, 2009 – RESprotect GmbH today announced that its anti-cancer drug RP101 is the first small molecule known to bind to heat shock protein Hsp27 and modulate its effect. High levels of Hsp27 have recently been detected in leukemias, osteosarcomas, malignant melanomas, and cancers of pancreatic, breast, ovarian, colon, liver, kidney, gastric, lung, endometrial, and prostate origin. Especially high levels of Hsp27 are observed in metastatic tissues compared to non metastatic tissues. Hsp27 is known to play a role in the following tumour cell functions: - Resistance to treatment with cytotoxic drugs
- Development of metastases
- Prevention of apoptosis
|
|
Read more...
|
|
|
Written by RESprotect GmbH
|
|
Tuesday, 31 March 2009 |
Enrollment In Phase 2 Clinical Trial For RP101 In Advanced Pancreatic Cancer Patients Completed
Dresden, Germany – March 31, 2009 – RESprotect´s development partner for North America, SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced that enrollment has been completed in the Company’s phase 2 clinical trial for RP101. The study is investigating a new treatment of late-stage pancreatic cancer. In 2007 RESprotect, the inventor of the RP101 technology granted the exclusive rights in the United States and Canada to develop and commercialize RP101, a clinical-stage compound for the treatment of cancer and other indications, to SciClone Pharmaceuticals, Inc. SciClone performs clinical studies with RP101, and the results are freely available to RESprotect. |
|
Read more...
|
|
|
Written by Bundesministerium für Wirtschaft und Technologie
|
|
Friday, 27 March 2009 |
 Berlin, 27. März 2009 - Dr. Bernd Pfaffenbach, Staatssekretär im Bundesministerium für Wirtschaft und Technologie (BMWi), hat heute in Berlin die Gewinner des Technologiewettbewerbes "THESEUS MITTELSTAND" bekannt gegeben.
Der Technologiewettbewerb "THESEUS MITTELSTAND 2009" wurde im Rahmen des Leuchtturmprojektes THESEUS durch das BMWi gestartet. Ziel ist es, kleinen und mittleren Unternehmen (KMU) die Chance zu eröffnen, das Internet der Zukunft mitzugestalten und auf der Basis von THESEUS-Zwischenergebnissen mit eigenen FuE-Arbeiten für neue Produkte, Verfahren und Dienste zu partizipieren. Aus einem großen Forschungsprojekt soll so ein frühzeitiger Technologietransfer von wissenschaftlichen Erkenntnissen in die mittelständische Wirtschaft erreicht werden.
|
|
Read more...
|
|
|
Written by RESprotect GmbH
|
|
Wednesday, 17 December 2008 |
|
The RESprotect GmbH has been nominated as one of the 14 finalists of the European Venture Contest Award 2008 out of 724 companies from all sectors and 24 countries
|
|
|
Written by RESprotect GmbH
|
|
Tuesday, 02 December 2008 |
|
The RESprotect GmbH has been nominated as a finalist of the STEP Award 2008.
|
|
|
Written by RESprotect GmbH
|
|
Thursday, 06 November 2008 |
|
On 6 November 2008, the RP101 program was awarded the 2008 Los Angeles Award in the Medical Research category.
|
|
|
Written by RESprotect GmbH
|
|
Wednesday, 22 October 2008 |
RESprotect grants South Korean License for its anti-cancer drug RP101 to Kwang Dong Pharmaceuticals, Inc.
Dresden, Germany – October 22, 2008 – RESprotect GmbH announced today that it has granted the exclusive rights in South Korea to develop and commercialize RP101, for the treatment of pancreatic cancer in South Korea, to Kwang Dong Pharmaceuticals, Inc., Seoul. RP101 is targeted at preventing tumor cells from developing resistance to chemotherapy, one of the most challenging areas for oncologists. RP101 is intended as co-treatment with cytotoxic drugs to prevent the development of resistance to chemotherapy. |
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 Next > End >>
|
| Results 8 - 14 of 59 |
News 
